SVB Securities analyst Mani Foroohar maintained a Buy rating on Talaris Therapeutics (TALS – Research Report) today and set a price target of $21.00. The company's shares closed last Thursday at $5.96, close to its 52-week low of $5.76. According to TipRanks.com, Foroohar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -26.1% and a 31.3% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, 4D Molecular Therapeutics, and Recursion Pharmaceuticals. Currently, the analyst consensus on Talaris Therapeutics is a Strong Buy with an average price target of $23.00.
https://www.tipranks.com/news/blurbs/svb-securities-thinks-talaris-therapeutics-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Talaris Therapeutics Charts.
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Talaris Therapeutics Charts.